A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM
NN1679-8505
Phase 1 other active
Quick answer
A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM for Healthy participants and participants with type 2 diabetes is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Healthy participants and participants with type 2 diabetes
- Phase
- Phase 1
- Modality
- other
- Status
- active